Roche steps up Merck challenge with first-line NSCLC approva...

Creating solutions, not products, in diabetes

Roche Diabetes Care’s Michael Goetzl explains how the company is spearheading a combined digital-pharmaceutical approach to diabetes and how pharma firms can best embrace holistic strategie

Mylan and Biocon launch Herceptin biosimilar in US

Mylan and Biocon have launched their Herceptin biosimilar Ogivri in the US, the second challenger to Roche’s breast and stomach cancer blockbuster.

Roche trumpets data for Soliris rival in NMOSD after US, EU ...

Drugs firms make massive discounts to get reimbursement in C...

Roche and Novartis are among the pharmaceuticals companies who have agreed to cut prices of some of their newest drugs by 61% on average to get them reimbursed in China, according to a repo

FDA cues up May verdict for Roche’s SMA challenger risdiplam